A combination of preoperative or intraoperative MB-PDT and surgery in the treatment of giant cutaneous squamous cell carcinoma with infection. (2021)

Peer-Reviewed Study · Xu L; Li X; Zhao C; Zhang X; Kou H; Yang Y; Zhu F; Zhang W; Lu Y · September 26, 2021

Xu L et al., 2021-09-26: Clinical case series of six patients with giant infected cutaneous squamous cell carcinoma treated with methylene blue PDT (635 nm, 120 J/cm2) before and during surgery: infection controlled in all six, flaps survived, no recurrence over 0.8-3 years – a genuine clinical use of methylene blue PDT in skin cancer, as an adjunct to surgery.

In 6 patients, the cSCC infection was completely controlled by MB-PDT, and the flap survival was 100%. There was no recurrence of cSCC in the follow-up of 1.6 years (range, 0.8-3 years) after the comminated treatment with MB-PDT and surgery.

Xu L et al., 2021-09-26: Clinical case series of six patients with giant infected cutaneous squamous cell carcinoma treated with methylene blue PDT (635 nm, 120 J/cm2) before and during surgery: infection controlled in all six, flaps survived, no recurrence over 0.8-3 years – a genuine clinical use of methylene blue PDT in skin cancer, as an adjunct to surgery. C8 Xu 2021 (methylene blue clinical record – skin). Study type: prospective clinical case series, N=6. Country: China. Dose: methylene blue PDT at 635 nm, 120 J/cm2, 100 mW/cm2, red LED, pre-operative and intra-operative; MB concentration not stated in the abstract. Funder/conflicts: not stated in the record. Comparator: none (uncontrolled). NOTE: the primary endpoint is infection control and surgical outcome, not tumour remission; methylene blue is used alongside, not instead of, surgery. Study type: uncontrolled series.